Cover Image
Market Research Report
Product code 

Global Autoinjectors Market Size, Share & Growth | Opportunities and Forecast, 2020-2027

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days


Back to Top
Global Autoinjectors Market Size, Share & Growth | Opportunities and Forecast, 2020-2027
Published: April 3, 2021
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • Description
  • Table of Contents

Global Autoinjectors Market is segmented By Type (Disposable Autoinjectors, Reusable Autoinjectors), By Technology (Manual Autoinjectors, Automated Autoinjectors), By Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, Others), By End User (Home Care Setting, Hospitals), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis,2020-2027

Market Overview

The Global Autoinjectors Market is expected to grow at a CAGR of 19.5% during the forecasting period (2020-2027).

Autoinjectors are easy-to-handle, and cost-effective small pen-shaped medical devices that contain a hypodermic needle and designed for self-administration of a dose of a specific drug by patients. Autoinjectors are spring-loaded pre-filled syringes that are particularly designed for easy and safe administration of the drugs even in the home care setting. The injectable drug delivery method is a technology-driven market, and technologically advanced autoinjectors have now replaced traditionally used self-injection devices, that were earlier used for the delivery of human growth hormones and insulin. Autoinjectors have reduced healthcare costs by reducing the number of visits to the hospital. Autoinjectors have several advantages, such as a reduction in needlestick injuries, needle phobia anxiety, and consistency regarding dose accuracy.

These devices are used for injecting life-saving drugs of anaphylaxis, diabetes, rheumatoid arthritis, multiple sclerosis, and other chronic and allergic diseases. As per the American Academy of Allergy Asthma and Immunology (AAAAI) in 2015 around 15 million people in the U.S. and as per the European Academy of Allergy and Clinical Immunology (EAACI) around 17 million people in Europe suffered from food allergies. The increasing prevalence of anaphylaxis globally is increasing demand for adrenaline, and epinephrine auto-injectors.

Market Drivers

The market is driven by the rising prevalence of chronic diseases and allergies, technological advancements, increasing regulatory approval, and ease in handling.

Major companies in the segment are coming up with advanced technology platforms and innovative devices. Companies are offering a variety of user-friendly drug delivery solutions such as Breeze™ technology by Nuance Designs that enables the creation of a new class of smaller, smarter drug delivery devices and Depot Control technology by Union Medico that ensures stability at needle penetration and LED light to prevent over-pressing. Other technologies include VapourSoft™ and ASI® technology by Bespak and Rotaject™ Pressure Release technology, NIT™ technology, and Pushclick™ technology by SHL Group. Some of the new features include one-handed operation, push-on-skin release, automatic reconstitution/priming, twist, and mix mechanism, anti-roll, compact and sleek design, LCD screens, and Bluetooth and other connectivity platforms.

Global Autoinjectors Market Restraints

Preference for alternative drug delivery modes and lack of development of autoinjectors for multiple drug viscosities are likely to hamper the growth of the market in the forecast period.

Segmentation Analysis

The global autoinjectors market can be segmented by type as disposable autoinjectors and reusable autoinjectors, by technology as manual autoinjectors and automated autoinjectors, by therapy as Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, and Others and by the end user as Home Care Settings, hospitals and ambulatory surgical centers.

Disposable autoinjectors are expected to dominate the market over the forecast period as they are easy to use and have a built-in glass syringe that makes it more convenient for patients with reduced handiness or visual impairments. The patient itself can use these autoinjectors without any prior training, which is not the case with eeusable autoinjectors. 

Among the various treatment options available for Rheumatoid Arthritis, autoinjectors are considered the most advanced and convenient mode of treatment. Rheumatoid arthritis is a chronic autoimmune disease that affects the connective tissue and causes swelling in joints resulting in pain, stiffness, and progressive loss of function. The disease generally affects connective tissues. According to the Global Healthy Living Foundation, around 350 million people have rheumatoid arthritis worldwide. Due to the rise in prevalence of rheumatoid arthritis, the market for autoinjectors is also growing.

Geographical Share

Geographically, the global autoinjectors market is divided into North America, Europe, South America, Asia-Pacific, and the Middle East and Africa.

North America is expected to hold a significant market share over the period of forecast. According to Food Allergy Research and Education, around 32 million Americans have food allergies, including 5.6 million children under the age of 18, that is one in every 13 children. Furthermore, as per a 2017 report by the Centre for Disease Control and Prevention (CDC), 54.4 million adults in the U.S. are suffering from some form of Arthritis. Rising prevalence of anaphylaxis and other allergies in the U.S. leads to faster FDA approvals of new devices, and an increase in chronic and autoimmune disorders are increasing the demand for self-administered drugs.

Europe is estimated to be the second largest market for autoinjectors owing to growing geriatric population, increasing cases of allergy and autoimmune disorders, favorable reimbursement scenario, and growing prescriptions for adrenaline autoinjectors by physicians. As per the World Allergy Organization, Hungry had the highest prevalence of anaphylaxis in 2017, with around 222 people suffering from food allergies out of 10.2 million population. Approximaetely 400,000 people in the UK suffer from rheumatoid arthritis. An increase in the number of incidences of allergy cases and prevalence in Europe is expected to boost the autoinjectors market during the forecast period.

Competitive Trends

Some of the major key players in the market are Kaleo, AbbVie, Amgen, Biogen Idec, AstraZeneca, Mylan, Pfizer, Teva Pharmaceuticals, Biogen, Eli Lilly, Merck & Co, Sandoz, Johnson&Johnson, Eli Lilly, YpsoMed, SHL Group, and Becton Dickinson and Company.

Most of the major companies are inclined towards new product launches and manufacturing of new drugs that are compatible with the autoinjectors.

In December 2018, YpsoMed launched YpsoMate® Smart, autoinjector that is an automated disposable injection device.

In October 2018, Amgen launched AMGEVITATM a biosimilar to adalimumab across the markets in Europe. AMGEVITA will be available in a prefilled syringe and pre-filled pen (SureClick® autoinjector) to support dosing according to the approved dosage recommendations in each indication.

In September 2018, Kaleo, announced the launch of AUVI-Q®, an epinephrine injection in Canada.

In June 2018, AbbVie and Eisai Co. announced that the autoinjection delivery system for HUMIRA® was listed in the National Health Insurance Drug Price Standard.

In May 2018, Amgen received EU approval for Repatha autoinjector.

In May 2018, Amgen announced that the US FDA approved Aimovig™ for the preventive treatment of migraine in adults. Aimovig 70 mg is self-administered once monthly via Amgen's device, the SureClick® autoinjector, and does not require a loading dose.

In April 2018, Kaleo announced the availability of AUVI-q® first and only FDA-approved epinephrine autoinjector for infants and toddlers

In April 2018, AbbVie and Samsung Bioepis signed a licensing agreement to launch Humira biosimilar in Europe.

In March 2018, GlaxoSmithKline started phase III study investigating Benlysta (belimumab) in combination with rituximab in adult patients with systemic lupus erythematosus. Benlysta is available as a 200mg single-dose autoinjector or prefilled syringe for subcutaneous injection.

Why purchase the report?

Visualize the composition of the autoinjectors market across each indication, in terms of type and by type highlighting the key commercial assets and players.

Identify commercial opportunities in autoinjectors by analyzing trends and co-development deals.

Excel data sheets with thousands of data points of autoinjectors market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key products of all major market players.

Target Audience:

Medical device companies

Hospitals and clinics

Research and consulting firms

Healthcare associations/institutes

Venture capitalists

Government agencies

Table of Contents

Table of Contents

1. Autoinjectors Market - Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Autoinjectors Market - Market Definition and Overview

3. Autoinjectors Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Technology
  • 3.3. Market Snippet by Therapy
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region
  • 3.6. DataM CLO Scenario

4. Autoinjectors Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • Rising prevalence of chronic diseases and allergies
      • Technological advancements
      • Increase in regulatory approval
      • Ease in handling
    • 4.1.2. Restraints
      • Preference for alternative drug delivery modes
      • Lack of development of autoinjectors for multiple drug viscosities
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Autoinjectors Market - Industry Analysis 

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis 
  • 5.3. Regulatory Analysis
  • 5.4. Epidemiology

6. Autoinjectors Market - By Type

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 6.3. Market Attractiveness Index, By Type
  • 6.4. Disposable Autoinjectors
    • 6.4.1. Introduction
    • 6.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 6.5. Reusable Autoinjectors

7. Autoinjectors Market - By Technology

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 7.3. Market Attractiveness Index, By Technology
  • 7.4. Manual Autoinjectors
    • 7.4.1. Introduction
    • 7.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 7.5. Automated Autoinjectors

8. Autoinjectors Market - By Therapy

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
  • 8.3. Market Attractiveness Index, By Therapy
  • 8.4. Rheumatoid Arthritis
    • 8.4.1. Introduction
    • 8.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 8.5. Multiple Sclerosis
  • 8.6. Diabetes
  • 8.7. Anaphylaxis
  • 8.8. Others

9. Autoinjectors Market - By End User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.3. Market Attractiveness Index, By End User
  • 9.4. Home Care Setting
    • 9.4.1. Introduction
    • 9.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 9.5. Hospitals

10. Autoinjectors Market - By Region

  • 10.1. Introduction 
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. U.S.
    • 10.4.2. Canada
    • 10.4.3. Mexico
  • 10.5. Europe
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Italy
    • 10.5.5. Spain
    • 10.5.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Brazil
    • 10.6.2. Argentina
    • 10.6.3. Rest of South America
  • 10.7. Asia-Pacific
    • 10.7.1. China
    • 10.7.2. India
    • 10.7.3. Japan
    • 10.7.4. Australia
    • 10.7.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa

11. Autoinjectors Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Competitor Autoinjectors Strategy Analysis
  • 11.3. Comparative Product Portfolio Analysis
  • 11.4. Market Positioning/Share Analysis
  • 11.5. Mergers and Acquisitions Analysis

12. Autoinjectors Market - Company Profiles

  • 12.1. Kaleo *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AbbVie
  • 12.3. Amgen
  • 12.4. Biogen Idec
  • 12.5. AstraZeneca
  • 12.6. Mylan
  • 12.7. Pfizer
  • 12.8. Teva Pharmaceuticals
  • 12.9. Biogen
  • 12.10. Eli Lilly
  • 12.11. Merck & Co
  • 12.12. Sandoz
  • 12.13. Johnson&Johnson
  • 12.14. YpsoMed
  • 12.15. Becton Dickinson and Company

13. Autoinjectors Market - Premium Insights

14. Autoinjectors Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us